Wave of promising study results raises hopes for coronavirus vaccines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update
July 21, 2020 8:42 AM EDTMorgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.
Risinger await results from BNT162b2(full spike)... More
